Nath Bio-genes (india) Ltd. · NSE:NATHBIOGEN
Nath Bio-genes (india) — Q4 FY24 Earnings Presentation
28 slides from Nath Bio-genes (india)'s earnings presentation, May 8, 2024
Slide 1: Cover letter to stock exchanges on audited results
08th May 2024 The Manager-Listing The Manager- Listing BSE Limited National Stock Exchange of India Ltd., Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra-Kurla Complex Dalal Street, Bandra (E) Mumbai-400001 Mumbai-400051 BSE Code-537291 NSE Code-NATHBIOGEN Dear Sir/Madam, Subject- Presentation on
Slide 2: Q4 & FY24 Investor Presentation
Nath Bio-Genes (India) Limited Q4 & FY24 Investor Presentation 1
Slide 3: Disclaimer
Disclaimer Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local political or economic developments, technological risks, and many other factors that could cause our actual
Slide 4: Sustainable Value Creation Strategy
Sustainable Value Creation Strategy 1 2 3 4 INVESTMENT TAILOR MADE PRODUCT STRONG R&D PRODUCTS PERFORMANCE FOCUS GRADE . BALANCE SHEET Customized High Yield and Bio-tech integrated Net Debt to Equity products to address Strong Pest and Innovation 0.05 x (FY24) key farmers’ Disease Resistance require
Slide 5: Competitive Positioning in a Competitive Sector
Competitive Positioning in a Competitive Sector Focus Area Product Selection • Build a dream-product basket with superior and diversified products • Build an Un-paralleled Supply Chain Network Winning Strategies • Focus on Cotton, Wheat, Maize & Fodder Bajra • Empower Stakeholders; Build long-term,
Slide 6: Business Growth Over Last 7 Years
Business Growth Over Last 7 Years Average Selling Price (Rs/kg) is Increasing Revenue Growth (INR Cr) 1296 CAGR 9.61% 333 192 480 171 128 FY18 FY24 FY18 FY24 Field Crops Vegetables 5
Slide 7: Tailor Made Products
Tailor Made Products Understand key farmer Develop products to Focus on disease and Stringent multistage requirements based on suit various agri climatic pest resistance which trials before commercial deep market research conditions automatically results in development higher yield 6
Slide 8: Continuous Research Focus
Continuous Research Focus ▪ Genetically Pure and Premium Quality Seeds ▪ Prioritize Disease and Pest resistance breeding ▪ Well Equipped, DSIR recognized R&D Innovation Centers ▪ Cold storage facilities, warehouses, and conditioning godowns having a capacity of 30,000MT ▪ R&D Team of experienced sci
Slide 9: Shareholder Value Creation Focus
Shareholder Value Creation Focus Growing Business Product Excellence Strong Positions in important crops Innovation and solution that drive productivity and create value for farmers Differentiated Customer Experience Margin Expansion Expanding market reach through new Growing EBITDA margins through
Slide 10: Our Super Success Stories
Our Super Success Stories Akhand Tomato Nath Sanket Super-27 Bajra Numerous other products in Pipeline 9
Slide 11: Nath Sanket – #1 BT Cotton Hybrid
Nath Sanket – #1 BT Cotton Hybrid Overview and Outlook Market Need: ▪ High level of resistance to sucking pest ▪ Leading BT-Cotton hybrid in the Market ▪ Yield losses ▪ Most preferred hybrid resistant to pink bollworm. What our R&D Produced: ▪ Less input cost with higher output. ▪ Worked with highly
Slide 12: wel See Ae Vey Mawar HUTT WaT
wel See Ae Vey Mawar HUTT WaT 21 Wa ead A Ae TMA TUT echt | fee a eT & wie wecelter ela & Hew carat or waul aed ar. ey a NBC 1111 BG II
Slide 13: Super 27 - The Challenger
Super 27- The Challenger Overview and Outlook Market Need ▪ High Yielding dual Purpose Hybrids ▪ Product is seeing strong traction. ▪ Crop window exploitation ▪ Tall plant size without lodging problem ▪ Dual purpose – grain and fodder Our R&D efforts ▪ Addressable market of 3000 tons ▪ NBIL is expec
Slide 14: Testimonials: Super-27
Testimonials: Super-27 Farmers on “Super-27” ‘We HT Aste UL-27 Ve HACE aTART e. Beh fete ole vd ang & ate sun aft Haeced fect &. Tos th eres are w feiv aft AevH sey wade... Wal SUPER-27
Slide 15: Akhand - Best Performing Hybrid Tomato Seed
Akhand- Best Performing Hybrid Tomato Seed Market Need Overview and Outlook ▪ Very deep red colour fruits with better shelf life ▪ Virus resistant hybrid ▪ Strong demand seen in the market ▪ Higher Yield ▪ Addressable market size of Rs 150 cr. ▪ Firm fruit fit for long transportation. Our R&D Effort
Slide 16: Farmers on Akhand
| Farmers on “Akhand” one cht feds UH decetar cance wat B, fiers wet sree Tee citer OT ele z. el Be Ud asiqd elot H Heo cia Ufedent h fee sug e ste sos erara aft FaEeAe. AKHAND (ntx-1312) ” 3
Slide 17: Q4FY24 Performance
Q4FY24 PERFORMANCE 16
Slide 18: Key Business Highlights
Key Business Highlights • Cotton sees continued expected growth • Paddy hybrid strategy remains effective • Bajra volume surges by 26% Crop Performance • Maize products show volume growth of 19% • Wheat volume witnesses a notable increase of 27% • WCW surges by 36% followed by Bio Tonic by 11 % in t
Slide 19: Key Operating and Financial Highlights
Key Operating and Financial Highlights Product Performance ▪ Cotton volumes increased by 17%. ▪ Paddy volumes increased by 11.99% highlighting increased Hybrid paddy’s share in product mix. ▪ Bajra segment delivered growth in value by 26% in FY24 vs FY23 ▪ Wheat grew in value by 26.86 % ▪ Non-Cotton
Slide 20: Segmental Revenue Contribution
Segmental Revenue Contribution FY24 Revenue FY23 Revenue INR 3,326 Mn INR 3,012 Mn Cotton,31% Cotton, 29% Others,44% Others, 45% Paddy ,25% Paddy, 26% Cotton Paddy Others Cotton Paddy Others • Others include: Jowar, Bajra, Maize, Mustard, Wheat, Vegetables & PNS 19
Slide 21: Segment wise Operating Performance
Segment wise Operating Performance Products UoM FY24 YOY Growth FY23 Cotton Packets in lakhs 16.06 16.38% 13.80 Paddy Quintals 61,349 11.99% 54,779 Other Crops Quintals 37,664 4.20% 36,144 Plant Nutrient (WCW) Litres 45,000 33.83% 33,625 20
Slide 22: Income Statement
Income Statement Particulars (INR Mn) Q4FY24 Q4FY23 %Change (YoY) FY24 FY23 %Change (YoY) Total Revenue 430 449 -4% 3,326 3,013 10% Gross Profit 316 283 12% 1,991 1,667 19% Gross Margin (%) 73% 63% 60% 55% EBITDA 45 41 10% 504 489 3% EBITDA Margin (%) 10% 9% 15% 16% Depreciation 10 10 -1% 33 30 8% F
Slide 23: Appendix
APPENDIX 22
Slide 24: Maintaining Profitability; Strong Balance Sheet
Maintaining Profitability; Strong Balance Sheet Net Debt (INR Mn) Net Worth (INR Mn) 6,133 6,107 5,576 5,734 888 5,420 5,076 4,692 679 659 672 576 478 3,033 363 328 207 1,071 1,213 -121 FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 EBITDA Margin
Slide 25: Visionary Leadership; Attracting the Best Talent
Visionary Leadership; Attracting the Best Talent Mr. N Kagliwal Mr. Satish Kagliwal Chairman MD Leadership Team Mr. Devinder Khurana Dr S Raina Dr VN Kulkarni Mr K Reddy Harish Pandey CFO Head – Genetic Research Head- R & D Head – Supply Chain Business Lead Nath Promoters are committed to sustainabl
Slide 26: Historical Income Statement
Historical Income Statement Nath Bio-Genes’ P&L Statement Particulars (INR Mn) FY24 FY23 FY22 FY21 FY20 Total Revenue 3,326 3,013 2,783 3,076 2,799 Gross Profit 1,991 1,667 1,544 1,715 1,536 Gross Margin (%) 60% 55% 56% 56% 55% EBITDA 504 489 373 667 547 EBITDA Margin (%) 15% 16% 13% 22% 20% Depreci
Slide 27: Historical Balance Sheet
Historical Balance Sheet Assets (INR Mn) FY24 FY23 FY22 FY21 FY20 Liabilities (INR Mn) FY24 FY23 FY22 FY21 FY20 Fixed Assets 2,406 2,340 2,329 2,333 2,308 Share Capital 190 190 190 190 190 Other Intangible 88 104 120 136 152 Assets Financial Assets 61 51 51 53 52 Reserves & Surplus 5,917 5,544 5,230
Slide 28: Thank You
Thank You CIN_NBIL_L01110MH1993PLC072842 For further information, please get in touch with: Sheetal Khanduja sheetal@GoIndiaadvisors.com M:+91 97693 64166 Deepika Sharma deepika@GoIndiaadvisors.com M:+918451029510 27
Nath Bio-Genes (India) — Q4 FY24 Earnings Presentation on 6ix